Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AEGR-733: Final Phase II data

Final data from a Phase II trial showed that 10 mg of AEGR-773 plus 10 mg of Zetia

Read the full 185 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE